Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
The medical management of atopic dermatitis (AD) has dramatically changed within the last few years due to the availability of an increasing number of biologics and Janus kinase inhibitors that have gained approval for use in patients with moderate to severe AD.
1 INTRODUCTION In 1971 Gianotti et al. first described benign cephalic histiocytosis (BCH) and up to the present approximately 70 cases have been reported in the literature.1, 2 In 2016 the Working Group of the Histiocyte Society published a revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages based on clinical, radiographic, pathological, phenotypic, genetic, and/or molecular features.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
